Moerae Matrix is a privately held biopharmaceutical company focused on the development of first-in-class targeted therapeutics for fibrotic diseases

MAPKAP kinase 2 (MK2) is a key terminal kinase in the TGF-ß/p38 signalling pathway and an important therapeutic target for fibrosis -more

MMI-0100 is a selective inhibitor of MK2 with excellent activity in multiple models of fibrosis and a promising pharmaceutical profile -more